Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Inks Contract with Janssen

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biomarker services company Proteome Sciences said today that it will analyze samples and perform other services for Janssen Pharmaceutica, a Johnson & Jonson company that specializes in developing drugs for mental health conditions.

Under the contract with Janssen, Proteome Sciences will combine its TMT isobaric mass tag technology, sample preparation, and bioinformatics with mass spectrometry services using Thermo Fisher Scientific's Orbitrap Velos.

Proteome Sciences' biomarker offerings include gel-based and gel-free proteomics tools and rapid assays to measure and test differential protein expression, as well as identifying and quantitating proprietary proteins in cells, body fluids, and tissues.

Financial terms of the agreement were not released.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.